JoVE Logo

Anmelden

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.

Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more drugs and are blocked faster than muscles with a lesser blood supply and a smaller blood flow. The drug's actions are terminated when redistributed to other tissues. The duration of action is directly correlated to the elimination half-life. Some drugs like pancuronium, d-tubocurarine, doxacurium and pipecuronium are excreted unchanged in the urine and have a long elimination half-life and duration of action lasting more than 60 minutes. Other drugs like atracurium and cisatracurium undergo spontaneous ester hydrolysis in plasma. Certain amino steroid blockers like vecuronium and rocuronium are metabolized in the liver. Although such metabolites have half the activity of the parent drug, they are usually not formed in amounts required to produce blockade. The drugs metabolized in the plasma or liver have a shorter elimination half-life and action duration lasting only 20 to 40 minutes. Other drugs are also excreted unchanged through the bile.

Tags

Nondepolarizing Neuromuscular BlockersPharmacokineticsIntravenous AdministrationMuscle Blood SupplyDrug RedistributionElimination Half lifePancuroniumD tubocurarineDoxacuriumPipecuroniumAtracuriumCisatracuriumVecuroniumRocuroniumSpontaneous Ester Hydrolysis

Aus Kapitel 7:

article

Now Playing

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Skeletal Muscle Relaxants

429 Ansichten

article

7.1 : Neuromuskuläre Verbindung und Blockade

Skeletal Muscle Relaxants

2.8K Ansichten

article

7.2 : Klassifizierung von Skelettmuskelrelaxantien

Skeletal Muscle Relaxants

2.4K Ansichten

article

7.3 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.4K Ansichten

article

7.4 : Nichtdepolarisierende (kompetitive) neuromuskuläre Blocker: Pharmakologische Wirkungen

Skeletal Muscle Relaxants

386 Ansichten

article

7.6 : Depolarisierende Blocker: Wirkmechanismus

Skeletal Muscle Relaxants

1.2K Ansichten

article

7.7 : Depolarisierende Blocker: Pharmakokinetik

Skeletal Muscle Relaxants

305 Ansichten

article

7.8 : Direkt wirkende Muskelrelaxanzien: Dantrolen und Botulinumtoxin

Skeletal Muscle Relaxants

653 Ansichten

article

7.9 : Skelettmuskelrelaxanzien: Nebenwirkungen

Skeletal Muscle Relaxants

332 Ansichten

article

7.10 : Skelettmuskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

462 Ansichten

article

7.11 : Spasmolytische Mittel: Chemische Klassifizierung

Skeletal Muscle Relaxants

852 Ansichten

article

7.12 : Peripher und zentral wirkende Muskelrelaxanzien: Ein Vergleich

Skeletal Muscle Relaxants

3.1K Ansichten

article

7.13 : Zentral wirkende Muskelrelaxanzien: Therapeutische Anwendungen

Skeletal Muscle Relaxants

616 Ansichten

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten